Surf Bio develops the Surf SnapShot™ technology to transform biologic delivery by enabling ultra-high concentration monoclonal antibody formulations. This proprietary polymer technology allows for subcutaneous injection of large doses in seconds, replacing lengthy intravenous infusions. The resulting patient-friendly delivery enables self-administration and potentially longer dosing intervals for biologics.
Funding
$17.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BMBVPXFounders
Product
Problem
Current methods of delivering monoclonal antibodies (mAbs) often require lengthy intravenous infusions, which can be inconvenient and limit accessibility for patients. High doses of mAbs can take hours to administer, requiring patients to visit clinics and be monitored by healthcare professionals.
Solution
Surf Bio has developed Surf SnapShot™ technology, a platform for rapid subcutaneous delivery of high-concentration biologics. This technology enables the delivery of mAb doses exceeding 1,000 mg in seconds via a standard autoinjector. The ultra-high concentration formulations are made possible by Surf Bio’s proprietary polymer, which enhances the accessibility and convenience of mAb and biologics administration. By reducing administration time from hours to seconds and enabling at-home self-administration, Surf Bio aims to improve patient adherence and reduce the burden on healthcare systems.
Target Audience
The primary target audience includes patients requiring frequent or high-dose monoclonal antibody treatments, as well as pharmaceutical companies seeking to improve the delivery and administration of their biologic products.
Features
- Rapid subcutaneous injection of monoclonal antibodies in seconds
- Ability to deliver mAb concentrations exceeding 600 mg/mL
- Delivery of doses over 1,000 mg in a single, standard autoinjector shot
- Proprietary polymer technology enabling ultra-high concentration formulations
- Potential for at-home self-administration, improving patient accessibility
- Reduced administration time compared to traditional intravenous infusions